Skip to content

United Therapeutics UTHR UHeart, UKidney, and UThymoKidney — Milestone payments paid

Similar metrics at other companies

OS Therapies logo
OSTXMilestone Payments
$22.38M0.0%
OS Therapies logo
OSTXMilestone Payments
$22.38M0.0%
Insmed logo
INSMPayment Of Milestone
$15M
CTO
CTORDevelopment Milestone Payments
$70M+155%
Arcus Biosciences logo
RCUSanti-CD39 — Milestone payments
$0
Insmed logo
INSMPayment Of Milestone
$15M

Other financials

Income statement

See full
Revenue$781.5M-1.6%
Gross profit$648.1M-7.7%
Operating income$325.8M-14.9%
Net income$274.9M-14.7%
EPS (diluted)$5.82-12.2%

Balance sheet

See full
Cash & equivalents$1.3B-32.6%
Total debt$12.2M
Total equity$5.9B-13.3%
Total assets$6.7B-13.3%

Cash flow

See full
Operating cash flow$463.3M+0.5%
CapEx$100.8M+34.6%
Free cash flow$362.5M-6.2%

Valuation

See full
Market cap$23B+84.1%
P/E17.9×+7.8×
P/S7.3×+3.2×

Profitability

See full
Gross margin86.6%-2.4pp
Operating margin45.3%-1.6pp
Net margin40.6%+0.2pp
FCF margin32.1%-5.6pp

Returns & leverage

See full
Return on equity20.3%+0.3pp
Debt / equity
Current ratio4.8×-0.7×

Where this comes from

Reported directly by United Therapeutics in its filing.

Tagged under the XBRL concept uthr:PaymentsForMilestoneAchievement.

The official record: United Therapeutics’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about United Therapeutics's uheart, ukidney, and uthymokidney — milestone payments paid.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is United Therapeutics's uheart, ukidney, and uthymokidney — milestone payments paid?
United Therapeutics (UTHR) reported uheart, ukidney, and uthymokidney — milestone payments paid of $625K in Q4 2025.
What does uheart, ukidney, and uthymokidney — milestone payments paid mean?
This metric tracks the actual cash outflows made during the reporting period to satisfy contractual milestone obligations for the UHeart, UKidney, and UThymoKidney programs. It reflects the successful achievement of development or commercial benchmarks that trigger payment to external partners or licensors. Monitoring this helps investors understand the pace of progress and the cash burn associated with specific R&D initiatives.